Longer duration of thalidomide monotherapy results in improved outcome in relapsed/refractory multiple myeloma

被引：2
|
作者：
von Liliefifeld-Toal, Marie [1 ]
Hahn-Ast, Corinna [1 ]
Bertolini, Francesco
Bila, Jelena
Boulin, Mathieu
Oakervee, Heather
Cibeira, Teresa
Cook, Gordon
Dmoszynska, Anna
Fenk, Roland
Guglielmelli, Tommasina
Goldschmidt, Hartmut
Hattori, Yukata
Myers, Bethan
Offidani, Massimo
Patriarca, Francesca
Petrucci, Maria Teresa
Pini, Massimo
Prince, Miles
Schey, Steve
Sonneveld, Pieter
Yakoub-Agha, Ibrahim
Waage, Anders
Glasmacher, Axel [1 ]
机构：
[1] Univ Bonn, D-5300 Bonn, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2725.2725
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2725
引用
收藏
页码：800A / 800A
页数：1
相关论文
共 50 条
  • [1] Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration
    Cibeira, M. Teresa
    Rosinol, Laura
    Ramiro, Laia
    Esteve, Jordi
    Torrebadell, Montserrat
    Blade, Joan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (06) : 486 - 492
  • [2] Thalidomide for the treatment of relapsed and refractory multiple myeloma
    Cool, RM
    Herrington, JD
    PHARMACOTHERAPY, 2002, 22 (08): : 1019 - 1028
  • [3] A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
    Glasmacher, A
    Hahn, C
    Hoffmann, F
    Naumann, R
    Goldschmidt, H
    Lilienfeld-Toal, M
    Orlopp, K
    Schmidt-Wolf, I
    Gorschlüter, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (05) : 584 - 593
  • [4] Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma - Is 100 mg daily enough?
    Radocha, J.
    Maisnar, V.
    Buchler, T.
    Maly, J.
    Hajek, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 167 - 167
  • [5] Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
    Palumbo, A
    Avonto, I
    Bruno, B
    Ambrosini, MT
    Bringhen, S
    Cavallo, F
    Falco, P
    Boccadoro, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (04) : 273 - 277
  • [6] Low dose thalidomide in patients with relapsed or refractory multiple myeloma
    Kees, M
    Dimou, G
    Sillaber, C
    Drach, J
    Ackermann, J
    Lechner, K
    Gisslinger, H
    LEUKEMIA & LYMPHOMA, 2003, 44 (11) : 1943 - 1946
  • [7] The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma
    Grover, JK
    Uppal, G
    Raina, V
    ANNALS OF ONCOLOGY, 2002, 13 (10) : 1636 - 1640
  • [8] Durable response to thalidomide in relapsed/refractory multiple myeloma (MM).
    Raza, SN
    Veksler, Y
    Sabir, T
    Li, ZJ
    Anderson, L
    Jagannath, S
    BLOOD, 2000, 96 (11) : 168A - 169A
  • [9] Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma:: better response rate with earlier treatment
    Maisnar, Vladimir
    Radocha, Jakub
    Buechler, Tomas
    Blaha, Vaclav
    Maly, Jaroslav
    Hajek, Roman
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (04) : 305 - 309
  • [10] Thalidomide in relapsed or refractory patients with multiple myeloma: Monotherapy or combination therapy? A report from systematic reviews.
    Glasmacher, A
    Hahn, C
    Hoffmann, F
    Furkert, K
    von Lilienfeld-Toal, M
    Orlopp, K
    Naumann, R
    Goldschmidt, H
    Schmidt-Wolf, IGH
    Gorschlueter, M
    BLOOD, 2005, 106 (11) : 364B - 364B
12345